Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Grant
Adjust height of sidebar
KMap
Grant
A First-in-Human Study of Mutant-Selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
Sponsored by Relay Therapeutics
Active
$249.4K Funding
2 People
External
Related Topics
cancer,
clinical trial,
drug development,
precision medicine,
treatment efficacy
People
Ruth Ca?amar
(CD)
Cancer Center Division
﹒Research Program Administration Officer III
Lizeth Evangelista
(CD)
Cancer Center Division
﹒Research Compliance Administrator II
